Skip to content

TAG Applauds Price Reduction of Molbioโ€™s Truenat Diagnostics for Tuberculosis

Statement / Press • 2023
Treatment Action Group (TAG) applauds Molbioโ€™s agreement with the Stop TB Partnership, USAID, and the Global Fund to reduce the price of Truenat diagnostic tests for tuberculosis (TB) from US$9 per test to $7.90 per test and to provide quality service and maintenance of Truenat testing instruments globally.

SMART4TB CONSORTIUM ANNOUNCES COMMUNITY PARTNERS

Statement / Press • 2023
Supporting, Mobilizing, and Accelerating Research for Tuberculosis Elimination (SMART4TB) is a five-year cooperative agreement made possible by the United States Agency for International Development (USAID), with the assistance of the American people,โ€ฏthat aims to transform tuberculosis (TB) prevention and care.

TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Companyโ€™s Action Falls Short of Community Demands

Statement / Press • 2023
After over a year of sustained advocacy from the TB community demanding that Johnson & Johnson publicly commit to non-enforcement or withdrawal of secondary patents on bedaquiline filed in 66 low- and middle-income countries (LMICs)...

The 1/4/6×24 Campaign Coalition Welcomes Indiaโ€™s Rejection of Johnson & Johnsonโ€™s Patent Evergreening Tactic

Statement / Press • 2023
The Indian Patent Office has taken a laudable step that will pave the way for generic manufacturing of a key tuberculosis (TB) drug.

For World TB Day, TB Advocates Demand Universal Access to Shorter, Safer TB Regimens

Statement / Press • 2023
On March 24, World Tuberculosis (TB) Day offers an opportunity to take stock of global progress against the deadliest disease in human history. This year, we face a sobering reality: since the start of the COVID-19 pandemic, rates of TB infection and death are higher than theyโ€™ve been since the early 2000s, setting back an already woefully inadequate effort to end the disease.

Call for Expression of Interest: Community Advisory Boards to Support Community Engagement in Research under the SMART4TB Project

Page • 2023The SMART4TB Consortium is calling for expressions of interest from multi-national community advisory boards (CAB) or similarly organized civil society organizations within three geographic focus areas to support community engagement in research in a new five-year research project funded by USAID.

CROI 2023 Tuberculosis Research Round Up

Statement / Press • 2023
Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI).

New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment

Statement / Press • 2022
We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.

Activists Across the World Demand Urgent Action to Improve Access to Lifesaving Tuberculosis (TB) Medicine, Bedaquiline

Statement / Press • 2022
A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global Fundโ€™s Expert Review Panel (ERP), an independent group of experts that reviews finished pharmaceutical products and makes recommendations on their use to the Global Fund.

Public Health Leaders, Researchers, and Activists Launch Global Campaign to Revolutionize Tuberculosis Prevention and Treatmnt with New, Shorter, Stronger, Safer, Evidence-Based Regimens

Statement / Press • 2022
As public health leaders, researchers, and civil society activists acting in solidarity with communities affected by tuberculosis (TB), we are dismayed by the continued global backslide in progress against historyโ€™s oldest pandemic.
Back To Top